Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
ELVN Enliven Therapeutics	$22.68 +5.7%	$19.93	$13.30 ▼ $30.03	$1.11B	0.83	304,008 shs	490,308 shs
GPCR Structure Therapeutics	$19.53 -0.4%	$22.00	$13.22 ▼ $45.37	$1.12B	-1.87	829,271 shs	377,215 shs
LFCR Lifecore Biomedical	$7.76 +1.0%	$7.26	$3.68 ▼ $8.85	$288.05M	0.71	228,332 shs	48,669 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.27%
ELVN Enliven Therapeutics	-0.88%	-0.56%	-7.06%	+29.82%	-12.94%
GPCR Structure Therapeutics	+1.92%	+2.62%	-4.72%	-9.93%	-56.11%
LFCR Lifecore Biomedical	-0.13%	-5.77%	+15.14%	+19.81%	+37.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	2.8145 of 5 stars	3.5	2.0	0.0	0.0	2.5	4.2	0.0
GPCR Structure Therapeutics	2.9103 of 5 stars	3.5	3.0	0.0	0.0	3.2	1.7	0.6
LFCR Lifecore Biomedical	1.3492 of 5 stars	1.3	1.0	0.0	0.0	3.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$41.20	81.70% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	290.10% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	3.16% Upside

Current Analyst Ratings Breakdown

Latest LFCR, CALT, ELVN, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
LFCR Lifecore Biomedical	$130.31M	2.20	N/A	N/A	$0.37 per share	20.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)

Latest LFCR, CALT, ELVN, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
ELVN Enliven Therapeutics	N/A	21.07	21.06
GPCR Structure Therapeutics	N/A	23.29	23.29
LFCR Lifecore Biomedical	66.36	2.71	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
ELVN Enliven Therapeutics	95.08%
GPCR Structure Therapeutics	91.78%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
ELVN Enliven Therapeutics	25.90%
GPCR Structure Therapeutics	9.43%
LFCR Lifecore Biomedical	32.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable

LFCR, CALT, ELVN, and GPCR Headlines

Recent News About These Companies

Lifecore Biomedical Insider Ups Holding During Year

July 7, 2025 | finance.yahoo.com

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Position Trimmed by Rhumbline Advisers

June 26, 2025 | marketbeat.com

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy

June 18, 2025 | kalkinemedia.comK

Lifecore Biomedical: Inflecting Financials Over Next 3 Years

June 18, 2025 | seekingalpha.com

Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement

June 17, 2025 | msn.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.comA

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17, 2025 | globenewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 15, 2025 | accessnewswire.comA

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale

June 14, 2025 | nasdaq.com

Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | finanznachrichten.de

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

June 12, 2025 | accessnewswire.comA

Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale

June 12, 2025 | msn.com

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

June 10, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

June 8, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

June 5, 2025 | accessnewswire.comA

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 3, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation

June 1, 2025 | accessnewswire.comA

Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago

May 29, 2025 | finance.yahoo.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025 | accessnewswire.comA

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 96,137 Shares

May 29, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR, CALT, ELVN, and GPCR Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 07/16/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Enliven Therapeutics NASDAQ:ELVN

$22.68 +1.22 (+5.66%)

As of 02:38 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics NASDAQ:GPCR

$19.52 -0.08 (-0.38%)

As of 02:38 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Lifecore Biomedical NASDAQ:LFCR

$7.76 +0.08 (+0.98%)

As of 02:38 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time